RESUMO
The RTS,S/AS01 is a subunit malaria vaccine against the pre-erythrocytic stage of Plasmodium falciparum. After over 30 years of research and development and clinical trials, this vaccine has been recommended by the WHO for use among children living in highly malaria endemic areas. Although the RTS, S/AS01 vaccine suffers from problems of a low protective efficacy (about 30%), need of four doses and short duration of protective immunity, this malaria vaccine is expected to save tens of thousands of children’s lives, and avoid tens of millions of malaria cases annually, because there have been tens of thousands of childhood deaths due to malaria recently. The introduction of the RTS, S/AS01 vaccine is therefore, widely accepted as a milestone in the history of battle against malaria, which brings a hope to contain malaria and even eventually eliminate malaria. Although there are still multiple challenges in the development of a satisfactory malaria vaccine, the success of the RTS, S/AS01 malaria greatly facilitates the progress towards the development of parasitic disease vaccines, and a more perfect malaria vaccine deserves expectations.
RESUMO
RTS, S/AS01 vaccine has recently been recommended by the WHO for large-scale uses in malaria-endemic areas, which is a milestone in the history of the fight against parasitic infections. Nevertheless, RTS, S/AS01 vaccine is not perfect. Hereby, the shortages of RTS, S/AS01 malaria vaccine were discussed, and the potential challenges during the research and development of next-generation malaria vaccines were analyzed.